Design of a phase 2 first-in-ADPKD clinical trial of the Sodium/Glucose Cotransporter-2 inhibitor (SGLT2i) empagliflozin”

4 December 2023

Presented by Stephen Seliger, M.S., M.D.

University of Maryland School of Medicine